Skip to main content
Premium Trial:

Request an Annual Quote

Agendia, Agilent Form Breast Cancer Dx Partnership

NEW YORK (GenomeWeb) – Agilent Technologies and Agendia announced today that they have partnered to develop a next-generation sequencing-based kit version of Agendia's molecular breast cancer diagnostics.

Under the terms of the deal, the companies will use Agilent's SureSelect target enrichment system to develop an RNA sequencing kit version of Agendia's microarray-based MammaPrint 70-gene breast cancer recurrence risk test and its BluePrint breast cancer subtyping assay.

According to the companies, the kit will enable Agendia to develop and perform the two tests as next-generations sequencing assays. The initial phase of the kit's development is expected to be completed this year, allowing for an early-access rollout in limited European markets.

Additional terms were not disclosed.

"The addition of Agilent's RNA next-generation sequencing technologies to our current microarray platform will allow us to penetrate international markets where decentralized kit offerings are preferred," Agendia CEO Mark Straley said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.